Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
In this issue: Knock on effects of the Valsartan recall, the future of...
Trending:
-
![]()
Will tumor-agnostic drug development help accelerate precision medicine approaches?
-
![]()
Emulate and AstraZeneca announce Organs-on-Chips partnership
-
![]()
LIDDS verifies NanoZolid for controlled release of cancer drugs
-
![]()
Merck’s Keytruda combo could be a winner for NSCLC and other solid tumours
-
![]()
ECCMID 2018: Ribaxamase demonstrates protection of the microbiome following Ceftriaxone treatment
-
![]()
Algorithm optimises peptides to target drug-resistant bacteria
Most Read
- Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
- Genentech doses first patient in Perjeta and Herceptin Phase 3 study
- Combining antibiotics with immune response to treat antibiotic resistant bacteria
- May’s top news stories
- Algorithm optimises peptides to target drug-resistant bacteria
Company A-Z
Latest Content
February’s top news stories
Eidos Therapeutics commenced a pivotal Phase III clinical trial of its investigational small molecule AG10 for the treatment of transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM), and Immatics is set to study its investigational therapy IMA101 in combination with Roche’s Tecentriq (atezolizumab) drug for the treatment of solid cancers. Drugdevelopment-technology.com wraps up key headlines from February 2019.
Caltag Medsystems Provides ELISA Kits Across a Range of Research Areas
Caltag Medsystems is pleased to provide enzyme-linked immunosorbent assay (ELISA) kits from many different suppliers.
IKA Laboratory Equipment Brochure
IKA helps your work be smarter, safer, and future-orientated, providing innovative solutions and products.
January’s top news stories
Janssen Pharmaceutical Companies of Johnson & Johnson unblinded the Phase III TITAN trial investigating Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
Eligen® Technology Mechanism of Action
Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.
Find out how pharma is fighting respiratory illnesses in the latest Pharma Technology Focus
In this issue: Knock on effects of the Valsartan recall, the future of AI in healthcare, the history of the Petri dish, and much more.
Validated Metal Analysis
Four commonly utilized carbohydrates for ptotein stabilization are Sucrose, Trehalose, Mannitol, and Maltose.
Paradigm Shift Regarding API and Formulation Components
This whitepaper will provide an introduction to high-purity carbohydrates often used for applications such as stabilisation, modulation, and cryopreservation, comparing the old paradigm that formulation components are inactive ingredients with limited functionality with the new paradigm, which suggests these components play a significant role in therapeutic stability, quality, potency, immunogenicity, and bioavailability.
Human and Animal Tissue Procurement
Caltag Medsystems has established agreements to procure both human and animal tissues.
Put it to the Test – Q&A with Charles Ischi
Charles Ischi answers questions about the process of selecting testing equipment for oral solid dose applications.
Latest News
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.
Go Top
